Skip to content
About
News
Blog
Investors
About
News
Blog
Investors
Search
Search
Close this search box.
Physician Login
SRT-100 Locator
Contact Us
Menu
About
About
Careers
Superficial Radiotherapy
Superficial Radiotherapy
Skin Cancer
Squamous Cell Carcinoma Treatment
Basal Cell Carcinoma Treatment
Alternative to Mohs Surgury
Keloid Treatment
Patient Outcomes
FAQ
News
Blog
Investors
Contact
The Wall Street Transcript
March 31, 2020
Back to Blog
Our CEO, Joseph C. Sardano, talks to TWST about Sensus Healthcare’s corporate strategy, investment thesis and growth opportunities — and our superficial radiation therapy and Directional Anisotropic Radiation Therapy (ART) platforms.
Prev
Previous Page
Next Page
Next
About
About
Careers
Superficial Radiotherapy
Superficial Radiotherapy
Skin Cancer
Squamous Cell Carcinoma Treatment
Basal Cell Carcinoma Treatment
Alternative to Mohs Surgury
Keloid Treatment
Patient Outcomes
FAQ
News
Blog
Investors
Contact
About
About
Careers
Superficial Radiotherapy
Superficial Radiotherapy
Skin Cancer
Squamous Cell Carcinoma Treatment
Basal Cell Carcinoma Treatment
Alternative to Mohs Surgury
Keloid Treatment
Patient Outcomes
FAQ
News
Blog
Investors
Contact
SRT-100 LOCATOR
Physician Login